What is the Prognostic Importance of Molecular Genetic Factors in Endometrial Carcinoma?
Authors:
E. Křepinská 1; M. Chmelařová 2; J. Laco 3; V. Palička 2; J. Špaček 1
Authors‘ workplace:
Porodnická a gynekologická klinika, LF UK a FN v Hradci Králové
1; Ústav klinické biochemie a diagnostiky, LF UK a FN v Hradci Králové
2; Fingerlandův ústav patologie, LF UK a FN v Hradci Králové
3
Published in:
Klin Onkol 2012; 25(4): 282-286
Category:
Original Articles
Overview
Background:
Evaluation of the importance of molecular genetic factors in endometrial carcinoma based on our review of available literature, and in the case of K- ras mutation based on our own data. The aim of the original part of our study was to compare the presence of K- ras mutation in early stages of endometroid carcinoma with normal endometrium and evaluate the role of the mutation in endometrial carcinogenesis.
Material and methods:
Molecular biological analysis was performed to detect K- ras mutation in samples of endometrial tissue obtained from women treated in the past at the Department of Obstetrics and Gynecology, University Hospital Hradec Kralove. The detection was made from DNA isolated from paraffin embedded sections using K- ras StripAssay™, ViennaLab Diagnostics GmbH.
Results:
K- ras mutation was found in 7 out of 30 specimens of endometroid carcinoma in stage I (23%) and in 3 of 20 specimens of normal endometrium in the control group (15%). K- ras mutations were more frequent in IA stage and grade 1 of endometroid carcinoma.
Conclusion:
The importance of molecular genetic factors in endometrial carcinoma differs depending on the type of carcinoma. In more common type 1 endometroid cancer, published data are not as clear as in type 2 carcinoma, in which prevalence of alteration of p53 reaches 90%. Results of our study performed on local population of women support the theory about the possible role of K- ras mutation as an early event in the process of endometrial carcinogenesis in type 1 tumors.
Key words:
endometrial carcinoma – K- ras gene – mutation
This study was supported by grant of Grant Agency of the Charles University No. 157310.
The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.
The Editorial Board declares that the manuscript met the ICMJE “uniform requirements” for biomedical papers.
Submitted:
12. 12. 2011
Accepted:
27. 6. 2012
Sources
1. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 1983; 15(1): 10– 17.
2. Liu FS. Molecular carcinogenesis of endometrial cancer. Taiwan J Obstet Gynecol 2007; 46(1): 26– 32.
3. Mutter GL. Pten, a protean tumor suppressor. Am J Pathol 2001; 158(6): 1895– 1898.
4. Esteller M, Levine R, Baylin SB et al. MLH1 promoter hypermethylation is associated with the microsatellite instability phenotype in sporadic endometrial carcinomas. Oncogene 1998; 17(18): 2413– 2417.
5. Caduff RF, Johnston CM, Frank TS. Mutations of the Ki- ras oncogene in carcinoma of the endometrium. Am J Pathol 1995; 146(1): 182– 188.
6. Saegusa M, Hashimura M, Yoshida T et al. Beta‑catenin mutations and aberrant nuclear expression during endometrial tumorigenesis. Br J Cancer 2001; 84(2): 209– 217.
7. Tashiro H, Isacson C, Levine R et al. p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis. Am J Pathol 1997; 150(1): 177– 185.
8. Catasus L, Machin P, Matias Guiu X et al. Microsatellite instability in endometrial carcinomas: clinicopathologic correlations in a series of 42 cases. Hum Pathol 1998; 29: 1160– 1164.
9. Lax SF. Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular‑based classification. Virchows Arch 2004; 444(3): 213– 223.
10. Tashiro H, Blazes MS, Wu R et al. Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res 1997; 57(18): 3935– 3940.
11. Tashiro H, Lax SF, Gaudin PB et al. Microsatellite instability is uncommon in uterine serous carcinoma. Am J Pathol 1997; 150(1): 75– 79.
12. Cibula D, Petruželka L et al. Onkogynekologie. Praha: Grada Publishing 2009.
13. Engelsen IB, Akslen LA, Salvesen HB. Biologic markers in endometrial cancer treatment. AMPIS 2009; 117(10): 693– 707.
14. Lax SF, Kurman RJ. A dualistic model for endometrial carcinogenesis based on immunohistochemical and molecular genetic analysis. Verh Dtsch Ges Patol 1997; 81: 228– 232.
15. Sasaki H, Nishii H, Takahashi H et al. Mutation of the Ki- ras protooncogene in human endometrial hyperplasia and carcinoma. Cancer Res 1993; 53(8): 1906– 1910.
16. Koul A, Willén R, Bendahl PO et al. Distinct sets of gene alteration in endometrial carcinoma implicate alternate modes of tumorigenesis. Cancer 2002; 94(9): 2369– 2379.
17. Kaku T, Kamura T, Hirakawa T et al. Endometrial carcinoma associated with hyperplasia – immunohistochemical study of angiogenesis and p53 expression. Gynecol Oncol 1999; 72(1): 51– 55.
18. Pilka R, Mickova I, Lubusky M et al. Expression of p53, Ki- 67, bcl- 2, c- erb- 2, estrogen, and progesterone receptors in endometrial cancer. Ceska Gynekol 2008; 73(4): 222– 227.
19. Pilka R, Markova I, Duskova M et al. Immunohistochemical evaluation and lymph node metastasi in surgically staged endometrial carcinoma. Eur J Gynaecol Oncol 2010; 31(5): 530– 535.
20. Bansal N, Yendluri V, Wenham RM. The molecular biology of endometrial cancers and implications for pathogenesis, classification, and targeted therapies. Cancer Control 2009; 16(1): 8– 13.
21. Risinger JI, Hayes K, Maxwell GL et al. PTEN mutation in endometrial cancers is associated with favorable clinical and pathological characteristics. Clin Cancer Res 1998; 4(12): 3005– 3010.
22. Okuda T, Sekizawa A, Purwosunu Y et al. Genetics of endometrial cancers. Obstet Gynecol Int 2010; 2010: 984013.
23. Maxwell GL, Risinger JI, Alvarez AA et al. Favorable survival associated with microsatellite instability in endometroid endometrial cancers. Obstet Gynecol 2001; 97(3): 417– 422.
24. Moreno‑Bueno G, Hardisson D, Sánchez C et al. Abnormalities of the APC/ b- catenin pathway in endometrial cancer. Oncogene 2002; 21(52): 7981– 7990.
25. Nei H, Saito T, Yamasaki H et al. Nuclear localization of b- catenin in normal and carcinogenic endometrium. Mol Carcinog 1999; 25(3): 207– 218.
26. Slomovitz BM, Broaddus RR, Burke TW et al. Her- 2/ neu overexpression and amplification in uterine papillary serous carcinoma. J Clin Oncol 2004; 22(15): 3126– 3132.
27. Williams JA Jr, Wang ZR, Parrish RS et al. Fluorescence in situ hybridization analysis of HER- 2/ neu, c- myc, and p53 in endometrial cancer. Exp Mol Pathol 1999; 67(3): 135– 143.
28. Krepinska E, Chmelarova M, Palicka V et al. Mutation of K- ras gene in carcinogenesis of endometrial carcinoma. Book of abstracts 13th Biennial Meeting of the International Gynecological Cancer Society, Prague, October 23– 26, 2010.
29. Krepinska E, Chmelarova M, Laco J et al. Mutation of K- ras gene in pathogenesis of endometrial carcinoma. Book of abstracts 17thInternational Meeting of the European Society of Gynaecological Oncology, Milan, Italy, September 11– 14, 2011.
30. Mizuuchi H, Nasim S, Kudo R et al. Clinical implications of K- ras mutations in malignant epithelial tumors of the endometrium. Cancer Res 1992; 52(10): 2777– 2781.
31. Ito K, Watanabe K, Nasim S et al. K- ras point mutations in endometrial carcinoma: Effect on outcome is dependent on age of patient. Gynecol Oncol 1996; 63(2): 238– 246.
32. Semczuk A, Berbec H, Kostuch M et al. K- ras gene point mutations in human endometrial carcinomas: correlation with clinicopathological features and patients‘ outcome. J Cancer Res Clin Oncol 1998; 124(12): 695– 700.
33. Esteller M, García A, Martínez- Palones JM, et al. The clinicopathological significance of K- RAS point mutation and gene amplification in endometrial cancer. Eur J Cancer 1997; 33(10): 1572– 1577.
34. Jones MW, Kounelis S, Hsu C et al. Prognostic value of p53 and K- ras- 2 topographic genotyping in endometrial carcinoma: A clinicopathologic and molecular comparison. Int J Gynecol Pathol 1997; 16(4): 354– 360.
35. Pijnenborg JM, Dam- de Veen GC, Kisters N et al. RASSF1A methylation and K- ras and B- raf mutations and recurrent endometrial cancer. Ann Oncol 2007; 18(3): 491– 497.
36. Prasad M, Wang H, Douglas W et al. Molecular genetic characterization of tamoxifen‑associated endometrial cancer. Gynecol Oncol 2005; 96(1): 25– 31.
37. Tsujioka H, Hachisuga T, Fukuoka M et al. Monitoring of Endometrial K- ras Mutation in Tamoxifen– Treated Patients With Breast Cancer. Int J Gynecol Cancer 2009; 19(6): 1052– 1056.
38. Koornstra JJ, Mourits MJ, Sijmons RH et al. Management of extracolonic tumours in patients with Lynch syndrome. Lancet Oncol 2009; 10(4): 400– 408.
39. Peltomäki P, Vasen HF, Bisgaard ML et al. Mutations predisposing to hereditary nonpolyposis colorectal cancer: database and results of a collaborative study. The International Collaborative Group on Hereditary Nonpolyposis Colorectal Cancer. Gastroenterology 1997; 113(4): 1146– 1158.
40. Schweizer P, Moisio AL, Kuismanen SA et al. Lack of MSH2 and MSH6 characterizes endometrial but not colon carcinomas in hereditary nonpolyposis colorectal cancer. Cancer Res 2001; 61(7): 2813– 2815.
41. Zhou XP, Kuismanen S, Nystrom- Lahti M et al. Distinct PTEN mutational spectra in hereditary non‑polyposis colon cancer syndrome‑related endometrial carcinomas compared to sporadic microsatellite unstable tumors. Hum Mol Genet 2002; 11(4): 445– 450.
Labels
Paediatric clinical oncology Surgery Clinical oncologyArticle was published in
Clinical Oncology
2012 Issue 4
Most read in this issue
- Hepatocellular Carcinoma – Long-Term Treatable Disease
- EGFR Mutations in Patients with Advanced NSCLC
- Treatment For Volume Upgrading of the Low-Grade Supratentorial Glioma After the Subtotal Neurosurgical Resection
- CT Colonography – Evolution of Methodology and Indications